Edward Li

Dr. Li is a Professor in the Department of Pharmacy Practice at the University of New England College of Pharmacy. Dr. Li earned his Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and his Master of Public Health from the University of New England.  He completed a Pharmacy Practice Residency at the University of Wisconsin Hospital and Clinics and an Oncology Pharmacy Practice Residency at the University of Maryland School of Pharmacy.  Dr. Li is a Board Certified Oncology Pharmacist who maintains a practice with the New England Cancer Specialists, the region’s largest oncology group, located in Scarborough, Maine.  He also works with New Century Health, a leading innovator of quality and cost management programs, to develop cancer treatment pathways.  Before joining UNE, he was the Oncology Pharmacy Manager at the National Comprehensive Cancer Network, a not-for-profit organization whose clinical practice guidelines in oncology are the standard of care in the United States. His research focuses on cancer pharmacoepidemiology, pharmacoeconomics, and evaluating health policy issues as they relate to oncology practice.  


Doctor of Pharmacy

Philadelphia College of Pharmacy


Master of Public Health

University of New England


Board Certifications and Licenses

Board Certified Oncology Pharmacist


Oncology Pharmacy Practice Residency

University of Maryland School of Pharmacy




Pharmacy Practice Residency

University of Wisconsin Hospital and Clinics




Oncology Pharmacy




Research Interests

Public Health Policy
Outcomes Research

Selected Publications

Schumock GT, Li EC, Wiest MD, Suda KJ, Stubbings J, Matusiak LM, Hunkler RJ, Vermeulen LC.  National trends in prescription drug expenditures and projections for 2017. Am J Health Syst Pharm. 2017 May 22. pii: ajhp170164. doi: 10.2146/ajhp170164.

Zelenetz AD, Ahmed I, Braud EL, Cross JD, Davenport-Ennis N, Dickinson BD, Goldberg SE, Gottlieb S, Johnson PE, Lyman GH, Markus R, Matulonis UA, Reinke D, Li EC, DeMartino J, Larsen JK, Hoffman JM. NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives. J Natl Comp Canc Netw. 2011;9[Suppl 4]:S1-S22.

Li EC, DeMartino JM. Preliminary Report: The Development of the NCCN Comparative Therapeutic Index as a Clinical Evaluative Process for Existing Data in Oncology. J Natl Comp Canc Netw. 2010;8[Suppl 5]:S1-S10.

Johnson PE, Dahlman G, Eng K, Garg R, Gottlieb S, Hoffman JM, Howell P, Jahanzeb M, Johnson S, Mackler E, Rubino M, Sarokhan B, Stewart FM, Tyler T, Vose JM, Weinstein S, Li EC, DeMartino J. NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for Stakeholders. J Natl Comp Canc Netw. 2010;8[Suppl 7]:S7-S27.


Other Scholarly Activity

Google Scholar Profile:


Edward Li, PharmD, MPH, BCOP

Edward Li




Portland Campus

Pharmacy Building


(207) 221-4120

On Campus